NCT07795411Recruiting
Prospective Multiomic Analysis in Small-Cell Lung Cancer
Prospective Multiomic Analysis in Small-Cell Lung Cancer to Inform Therapeutic Vulnerabilities and Predict Clinical Outcomes: Deep Phenotyping of Relapsed SCLC Cohort
Source: ClinicalTrials.gov · Last updated 2 Oct 2026
Brief summary (registry, in English)
This is an observational study to collects blood samples and tumor tissue from adults with relapsed small-cell lung cancer (SCLC) receiving standard of care commercial DLL3 T cell engager. The goal of the study is to understand the changes in tumor markers over time and examine whether these changes are associated with clinical outcomes. Participants will provide blood samples and, when clinically feasible, tumor tissue during routine care visits, treatment, and imaging assessments. The study does not assign cancer treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 26 Aug 2026
- Start date
- 25 Nov 2026
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Diseases
- Lung cancer
- NCT number
- NCT07795411
What you commit to
- Study type: Observational
- Planned participants: 30
- From 25 Nov 2026 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- There will be no specific restrictions with respect to performance status, organ function, or prior/concurrent modes of therapy other than that the patient must be able to tolerate venipuncture and any planned interventional radiology or surgical procedures deemed necessary by their treating physicians.
Other
- Prisoners or incarcerated patients
- Those with cognitive impairments lacking decision-making capacity are excluded.
Who the study is looking for
- 18 years of age or older
- Confirmed pathologic diagnosis of active SCLC or neuroendocrine cancer.
- Relapsed small cell lung cancer (SCLC) planning to receive commercial DLL3 bispecific T cell engager.
- Willing to provide informed consent.
- Willing to provide blood samples and undergo tissue biopsy at various time points throughout the study, collected in concurrence with treatment cycles and/or imaging visits
- Patients with multiple primary malignancies, recurrent lung cancer, or mixed histology are not excluded.
- Patients who have contraindications or are unable to receive immunotherapy will be eligible for the study, and their samples will be used for comparison and control.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ohio State University Comprehensive Cancer Center Coordinator of this site? Confirm its status | Columbus | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.